Platinum-based regimens play an essential role in triple-negative breast cancer (TNBC) treatment, with the CBCSG006 study establishing the position of gemcitabine plus cisplatin (GP) as a first-line treatment of metastatic TNBC. Our study aims to further improve the efficacy of the first-line platinum-based chemotherapy for metastatic TNBC by optimizing the selection of platinum.
ESMO Open published a clinical update in Oncology on 19 Mar 2026.
The item focuses on A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer☆.
Review the original article for the full source wording and details.